

## SAFETY DATA SHEET



### \* 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

<b>Material</b>	OS-CAL 500+D [600 IU] CAPLETS																
<b>Synonym(s)</b>	OS-CAL 500 MG + D [600 IU] TABLETS * OS-CAL 500 + 600 IU VITAMIN D (US) * CALCIUM CARBONATE AND VITAMIN D, FORMULATED PRODUCT * PROJECT INDY * MFC 50748																
<b>Recommended Use</b>	Food																
<b>Company Name</b>	<p>GlaxoSmithKline UK 980 Great West Road Brentford, Middlesex TW8 9GS UK UK General Information (normal business hours): +44-20-8047-5000</p> <p>GlaxoSmithKline US 5 Moore Drive Research Triangle Park, NC 27709 USA US General Information (normal business hours): +1-888-825-5249</p> <p>Email Address: <a href="mailto:msds@gsk.com">msds@gsk.com</a> Website: <a href="http://www.gsk.com">www.gsk.com</a></p> <p>EMERGENCY PHONE NUMBERS - TRANSPORT EMERGENCIAS (by country / geographic region):</p> <table border="0"> <tr> <td>Africa (Arab-speaking):</td> <td>+961-3-487-287 (Lebanon)</td> </tr> <tr> <td>Africa (English, French, Portuguese-speaking):</td> <td>+44-208-762-8322 (UK)</td> </tr> <tr> <td>Asia Pacific (except China):</td> <td>+65-633-44-177 (Singapore)</td> </tr> <tr> <td>China:</td> <td>+86-10-5100-3039 (Beijing)</td> </tr> <tr> <td>EU:</td> <td>+44-208-762-8322 (UK)</td> </tr> <tr> <td>Israel:</td> <td>+44-208-762-8322 (UK)</td> </tr> <tr> <td>Middle East (except Israel):</td> <td>+961-3-487-287 (Lebanon)</td> </tr> <tr> <td>US:</td> <td>+1-703-527-3887 (US)</td> </tr> </table> <p>available 24 hrs/7 days; multi-language response</p> <p>MEDICAL EMERGENCIAS: +1-612-221-3999, Ext 221 (US) available 24 hrs/7 days; multi-language response</p>	Africa (Arab-speaking):	+961-3-487-287 (Lebanon)	Africa (English, French, Portuguese-speaking):	+44-208-762-8322 (UK)	Asia Pacific (except China):	+65-633-44-177 (Singapore)	China:	+86-10-5100-3039 (Beijing)	EU:	+44-208-762-8322 (UK)	Israel:	+44-208-762-8322 (UK)	Middle East (except Israel):	+961-3-487-287 (Lebanon)	US:	+1-703-527-3887 (US)
Africa (Arab-speaking):	+961-3-487-287 (Lebanon)																
Africa (English, French, Portuguese-speaking):	+44-208-762-8322 (UK)																
Asia Pacific (except China):	+65-633-44-177 (Singapore)																
China:	+86-10-5100-3039 (Beijing)																
EU:	+44-208-762-8322 (UK)																
Israel:	+44-208-762-8322 (UK)																
Middle East (except Israel):	+961-3-487-287 (Lebanon)																
US:	+1-703-527-3887 (US)																

### 2. HAZARDS IDENTIFICATION

<b>Fire and Explosion Hazards</b>	Expected to be non-combustible.
<b>Health</b>	Skin irritant. Severe eye irritant. Health effects information is based on hazards of components.
<b>Environment</b>	No information is available about the potential of this product to produce adverse environmental effects.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
(+/-)-A-TOCOPHEROL	10191-41-0	< 0.01	233-466-0
CALCIUM CARBONATE	471-34-1	83.73	207-439-9

Material OS-CAL 500+D [600 IU] CAPLETS

CHOLECALCIFEROL	67-97-0	< 0.01	200-673-2
Other components below reportable levels		16.25	

#### 4. FIRST-AID MEASURES

<b>Ingestion</b>	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
<b>Inhalation</b>	Physical form suggests that risk of inhalation exposure is negligible.
<b>Skin contact</b>	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
<b>Eye contact</b>	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

#### NOTES TO HEALTH PROFESSIONALS

<b>Medical Treatment</b>	Because of the potential for acute or delayed eye damage, consider referral to an ophthalmologist.
<b>Medical Conditions Caused or Aggravated by Exposure</b>	None for occupational exposure.
<b>Antidotes</b>	No specific antidotes are recommended.

#### 5. FIRE-FIGHTING MEASURES

<b>Fire and Explosion Hazards</b>	Not expected for the product, although the packaging is combustible.
<b>Extinguishing Media</b>	Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.
<b>Special Firefighting Procedures</b>	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
<b>Hazardous Combustion Products</b>	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

#### 6. ACCIDENTAL RELEASE MEASURES

<b>Personal Precautions</b>	Wear protective clothing and equipment consistent with the degree of hazard.
<b>Environmental Precautions</b>	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
<b>Clean-up Methods</b>	Collect and place it in a suitable, properly labelled container for recovery or disposal.
<b>Decontamination Procedures</b>	No specific decontamination or detoxification procedures have been identified for this product.

#### 7. HANDLING AND STORAGE

##### HANDLING

**General Requirements** No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

##### STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

Material OS-CAL 500+D [600 IU] CAPLETS

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

## OCCUPATIONAL EXPOSURE LIMITS

<b>INGREDIENT</b>	CHOLECALCIFEROL
<b>GSK Occupational Hazard Category</b>	5
<b>GSK Occupational Exposure Limit</b>	0.2 mcg/m3 (8 HR TWA)

## PERSONAL PROTECTIVE EQUIPMENT

<b>Eye Protection</b>	Wear approved safety glasses with side shields if eye contact is possible.
<b>Other Equipment or Procedures</b>	Follow all local regulations if personal protective equipment (PPE) is used in the workplace. Wash hands and arms thoroughly after handling. An eye wash station should be available.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

## Appearance

<b>Physical Form</b>	Tablet.
----------------------	---------

## 10. STABILITY AND REACTIVITY

<b>Stability</b>	This product is expected to be stable.
<b>Conditions to Avoid</b>	None for normal handling of this product.

## 11. TOXICOLOGY INFORMATION

## Routes of Exposure

<b>Oral Toxicity</b>	Not expected to be toxic following ingestion.
<b>Inhalation Toxicity</b>	No studies have been conducted.
<b>Skin Effects</b>	Irritation might occur following direct contact.
<b>Eye Effects</b>	Severe irritation might occur following direct contact with eyes.
<b>Sensitisation</b>	Sensitisation (allergic skin reaction) is not expected.
<b>Genetic Toxicity</b>	Not expected to be genotoxic under occupational exposure conditions.
<b>Carcinogenicity</b>	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA. Not expected to produce cancer in humans under occupational exposure conditions.
<b>Reproductive Effects</b>	Not expected to produce adverse effects on fertility or development under occupational exposure conditions.
<b>Other Adverse Effects</b>	None known for occupational exposure.

## 12. ECOLOGICAL INFORMATION

<b>Summary</b>	No information is available about the potential of this product to produce adverse environmental effects. Local regulations and procedures should be consulted prior to environmental release.
----------------	--

## 13. DISPOSAL CONSIDERATIONS

<b>Disposal Recommendations</b>	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
<b>Regulatory Requirements</b>	Observe all local and national regulations when disposing of this product.

## \* 14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

## UN Classification and Labelling

<b>Transport Information</b>	Not regulated in transport.
------------------------------	-----------------------------

15. REGULATORY INFORMATION
----------------------------

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

**EU Classification and Labelling**

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

**US OSHA Standard (29 CFR Part 1910.1200)**

**Classification** Exempt when packaged for sale to consumers in a retail establishment.

**Other US Regulations**

**TSCA Status** Exempt

16. OTHER INFORMATION
-----------------------

**References** GSK Hazard Determination

**SDS Version Number** 2

**SDS Sections Updated****Sections**

IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF  
COMPANY  
TRANSPORT INFORMATION

**Subsections**

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.